Dra. María Alejandra Torres Viera

#Hematology Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell #Lymphoma | Journal of Clinical Oncology ⁦@JCO_ASCO⁩ #lymsm ascopubs.org/doi/10.1200/JC…

FDA drug trials exclude a widening slice of Americans, research reveals medicalxpress.com/news/2025-12-f… via @medical_xpress

Presented at #EHA2025: Among patients with chronic lymphocytic leukemia, undetectable MRD and progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years. Full FLAIR phase 3 trial results: nej.md/3SMNdC4  @eha_hematology

Acquired thrombotic thrombocytopenic purpura of unknown cause (uTTP) accounts more than 20% of cases of thrombotic thrombocytopenic purpura (TTP). A new study from the French TTP research team explores how uTTP responds to treatment. haematologica.org/article/view/h…

CONGRESS | #EHA2025 | PRESENTATION Daniel Kerr, @TGHCares Tampa General Cancer Institute, presents updated results from the epcoritamab + pola-R-CHP cohort of the phase Ib/II EPCORE NHL-5 trial (N = 37). Fixed-duration epcoritamab + pola-R-CHP in patients with newly diagnosed DLBCL, with follow-up of 16.1 months, continues to show high ORR (100%) and CR rates (97%), with high response rates observed across subgroups. There were no new safety signals. These results compare favorably to other 1L regimens in this patient population, suggesting that further exploration is warranted. Follow our live feed for more updates: lymphomahub.com/medical-inform… #lymphoma #lymsm #MedicalCongress

CONGRESS | #EHA2025 | POSTER Justin Darrah, Cedars-Sinai Medical Center shares the results of a match-adjusted comparative analysis demonstrating the benefit of adding epcoritamab to R-DHAX/C or R-ICE vs chemoimmunotherapy regimens alone in pts with R/R DLBCL intended for transplant. Epcoritamab + R-DHAX/C or R-ICE provided an 83% reduction in the risk of disease-progression and a 92% reduction in the risk of mortality compared to R-DHAX/C or R-ICE. Adding epcoritamab to R-DHAX/C or R-ICE provides a significant 2.9-fold increase in the proportion of complete responders eligible for consolidation, and provides significant improvements in survival outcomes in pts with transplant-eligible R/R DLBCL. Follow our live feed for more updates: loom.ly/eNbvVvk #lymphoma #lymsm #MedicalCongress

CONGRESS | #EHA2025 | PRESENTATION Viola Pöschel, @Saar_Uni Saarland University Medical School, highlights results from a phase III trial assessing interim PET adapted treatment reduction in elderly patients with DLBCL with a favorable prognosis (N = 288). PET-4 adapted treatment with R-CHOP resulted in excellent PFS and OS outcomes and reduced treatment exposure in 2/3 of elderly patients with favorable DLBCL. Follow our live feed for more updates: lymphomahub.com/medical-inform… #lymphoma #lymsm #MedicalCongress

T Cells Take Up Residence in the Healthy Brain Via a Gut-Fat-Brain Axis m.yale.edu/c6rf

A study led by Dr. Malpica of our Rare Lymphoma Section found adult T-cell leukemia or lymphoma and extranodal NKT-cell lymphoma are more prevalent among Latin Americans (LA), calling for greater LA participation in global T cell lymphoma research. tinyurl.com/PTCL-Latin

Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma buff.ly/NEoLEba

Esta maravilloso paper es el resultado del esfuerzo colaborativo del grupo GELL . Gracias a uds todos expertos latinoamericanos.

Carcasbella 1 de enero 2025. Aqui vamos #Bienvenido2025

🧵 TRIANGLE Trial Update: The Role of ASCT in Mantle Cell Lymphoma (MCL) 📊FFS and OS 🆕️Analysis based on p53 expression: 🔹Low p53 (<50%): No clear benefit of ASCT (HR:0.85) 🔹High p53 (>50%): ASCT improves outcomes (HR:0.68) 🔑In high-risk MCL, ASCT still matters! #Lymphoma

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma nejm.org/doi/full/10.10…

The safety and high activity of N-AVD will lead to a new standard of care for most older patients with Hodgkin lymphoma if confirmed by longer follow-up of S1826; frail patients ineligible for anthracyclines require alternative approaches. @JCO_ASCO ascopubs.org/doi/full/10.12…

Ibrutinib–R-mini-CHOP improves PFS compared with historical rates reported for R-mini-CHOP, but this study did not demonstrate a superior OS. ow.ly/LxZ350U5wmR #clinicaltrialsandobservations #lymphoidneoplasia

AML: AZA + VEN. ashpublications.org/blood/article/…

Update on older adults in S1826 @DrAEvens #ISHL13 (T077): - 99 pts age >60y, median f/u now 2.1 yrs - 2-yr PFS 89% N-AVD (64% BV-AVD) - 2-yr OS 96% N-AVD (85% BV-AVD) - 16% NRM in BV-AVD arm (!!!) vs 6% N-AVD is SOC in older adults with AS cHL. #lymsm onlinelibrary.wiley.com/doi/full/10.10…

CONGRESS | #SOHO2024 Stephen M Ansell, @MayoClinic, discusses whether ABVD and BEACOPP are still relevant for the treatment of advanced stage Hodgkin #lymphoma. He believes that A(B)VD chemotherapy still has a role for low-risk patients, while younger patients or those with high-risk may benefit more from newer treatments such as Nivo-AVD and BrECADD. He also mentions that EscBEACOPP is no longer relevant and that BrECADD has replaced it as the current standard. #lymsm #MedicalCongress

Three patients of mine treated with Mosun at 1.6mg q3weeks back in 2016, have remained in remission. Mosun was approved in 12.2022. The GO29781 clinical trial gave them access to “tomorrow’s medicine” 6 years earlier.